Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Delgocitinib - Japan Tobacco/LEO Pharma

Drug Profile

Delgocitinib - Japan Tobacco/LEO Pharma

Alternative Names: CORECTIM; JTE-052; JTE-052A; LEO 124249; LEO 124249 cream; LP-0133

Latest Information Update: 10 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Japan Tobacco
  • Developer Japan Tobacco; LEO Pharma
  • Class Anti-inflammatories; Antiallergics; Antipsoriatics; Azetidines; Nitriles; Pyrimidines; Pyrrolidines; Skin disorder therapies; Small molecules; Spiro compounds
  • Mechanism of Action Janus kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Atopic dermatitis
  • Preregistration Eczema
  • Phase II Alopecia areata; Autoimmune disorders; Discoid lupus erythematosus; Hypersensitivity; Inverse psoriasis

Most Recent Events

  • 03 May 2024 LEO Pharma announces intention to launch elgocitinib for Eczema in the EU in Q4 2024
  • 09 Mar 2024 Efficacy and adverse events data from a phase III OLE DELTA-3 trial in Eczema released by LEO Pharma
  • 08 Mar 2024 Pharmacokinetics data from a phase I trial in Eczema (In volunteers) presented at the American Academy of Dermatology Annual Meeting 2024 (AAD-2024)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top